INDINAVIR/ RITONAVIR/ AMPRENAVIR REGIMEN IN HIV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项药代动力学先导性研究，旨在研究用于HIV感染的三种蛋白酶抑制剂的药物相互作用。它将评估加入FOS-APV对HIV感染患者的药物动力学参数、峰浓度、消除半衰期和稳态浓度-时间曲线下面积的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a pharmacokinetic pilot study to investigate drug interactions of three protease inhibitors used in HIV infections. It will evaluate the impact of the addition of fos-APV on the pharmacokinetic parameters, the peak aconcentrations, the elimination half-life, and the area under the concentration-time curve of Indinavir, Ritonavir/Amprenavir at steady state in HIV infected patients.